<DOC>
	<DOCNO>NCT01392495</DOCNO>
	<brief_summary>This study extension study CQTI571A2102 evaluate long-term safety , tolerability efficacy QTI571 ( imatinib ) severe pulmonary arterial hypertension patient .</brief_summary>
	<brief_title>Extension CQTI571A2102 Evaluate Long-term Safety , Tolerability Efficacy Imatinib Severe Pulmonary Arterial Hypertension ( PAH )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Patients complete CQTI571A2102 clinical trial include Study Completion assessment end study visit meet eligibility criterion study meet withdrawal criterion safety reason study conduct Patients leave ventricular ejection fraction ( LVEF ) &lt; 45 % Patients thrombocytopenia , platelet count &lt; 50 x109/L ( 50 x 103/ÂµL ) . Patients uncontrolled systemic arterial hypertension , systolic pressure &gt; 160 mmHg diastolic pressure &gt; 90 mmHg . Patients QTcF &gt; 450 m male &gt; 470 m female absence right bundle branch block . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Pulmonary arterial hypertension</keyword>
	<keyword>imatinib</keyword>
	<keyword>6MWD</keyword>
</DOC>